Summary
Omalizumab-treated participants showed significant decreases in IL-4peanut-reactive CD4 T cells and plasmacytoid dendritic cells
MILWAUKEE, Feb. 23, 2026 /PRNewswire/ — Omalizumab, both as a monotherapy and for oral immunotherapy (OIT), modulates specific T cell and dendritic cell (DC) subsets, …
Source: PR Newswire
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
